ClearPoint Neuro to Announce Third Quarter 2020 Results on November 10

Rhea-AI Summary

ClearPoint Neuro (Nasdaq: CLPT) will release its 2020 third quarter financial results on November 10, 2020, after market close. A conference call to discuss the results will follow at 4:30 p.m. Eastern. Interested participants can join via phone or through a live webcast on the company's website. ClearPoint Neuro focuses on improving therapies for neurological disorders with its FDA-cleared ClearPoint® Neuro Navigation System, currently installed in 60 clinical sites. Risks include uncertainties related to COVID-19 and future revenue generation from its products.

Positive

• ClearPoint's Neuro Navigation System is FDA-cleared and CE-marked, enhancing credibility.
• Product installed in 60 active clinical sites, showcasing market penetration.
• SmartFlow® cannula in collaboration with 25 drug delivery companies indicates strong industry interest.
• Over 4,000 procedures supported, demonstrating demand and operational capability.

Negative

• Future revenues are uncertain, with risks associated with COVID-19 impacting business.
• Market acceptance of the Neuro Navigation System is uncertain, potentially affecting sales.

Release and Call After Market Close

IRVINE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 third quarter, which ended September 30, 2020, on Tuesday, November 10, 2020 after the market close. The Company will subsequently conduct a conference call and webcast that day to review its results at 4:30 p.m. Eastern (1:30 p.m. Pacific).

Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada. Callers should dial in at least 5 minutes prior to the call start time.

A live and archived webcast may be accessed by visiting the company's website at www.clearpointneuro.com, by selecting “Investors” / “News” / “IR Calendar.”

A replay of the conference call will be available shortly after completion of the call until December 10, 2020, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference ID number 413671.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint^® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States. The Company’s SmartFlow^® cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Company’s cash resources. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2020, which the Company intends to file with the Securities and Exchange Commission on or before November 16, 2020.

Contact:
Harold A. Hurwitz, Chief Financial Officer
(949) 900-6833
info@clearpointneuro.com

Jacqueline Keller, Vice President, Marketing
(949) 900-6833
info@clearpointneuro.com

FAQ

When will ClearPoint Neuro release its financial results for Q3 2020?

ClearPoint Neuro will release its financial results on November 10, 2020, after market close.

What time is the ClearPoint Neuro conference call scheduled for?

The conference call is scheduled for 4:30 p.m. Eastern on November 10, 2020.

How can I participate in the ClearPoint Neuro conference call?

Participants can join the conference call by dialing (877) 407-9034 from within the U.S. or (201) 493-6737 from outside the U.S. or Canada.

What products does ClearPoint Neuro offer?

ClearPoint Neuro offers the ClearPoint® Neuro Navigation System and SmartFlow® cannula for various neurological procedures.

What risks does ClearPoint Neuro face regarding its future performance?

Key risks include the uncertainty of future revenues and market acceptance of its products, impacted by COVID-19.